TW202342044A - Cdk4及6抑制劑及氟維司群用於治療先前以cdk4及6抑制劑治療的患者之荷爾蒙受體陽性、人類表皮生長因子受體2陰性之晚期或轉移性乳癌 - Google Patents

Cdk4及6抑制劑及氟維司群用於治療先前以cdk4及6抑制劑治療的患者之荷爾蒙受體陽性、人類表皮生長因子受體2陰性之晚期或轉移性乳癌 Download PDF

Info

Publication number
TW202342044A
TW202342044A TW111147357A TW111147357A TW202342044A TW 202342044 A TW202342044 A TW 202342044A TW 111147357 A TW111147357 A TW 111147357A TW 111147357 A TW111147357 A TW 111147357A TW 202342044 A TW202342044 A TW 202342044A
Authority
TW
Taiwan
Prior art keywords
cdk4
inhibitor
therapy
fulvestrant
treatment
Prior art date
Application number
TW111147357A
Other languages
English (en)
Chinese (zh)
Inventor
萊西 摩根 利奇菲爾德
基瑪拉斯 克勞迪亞 莫拉托
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202342044A publication Critical patent/TW202342044A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111147357A 2021-12-10 2022-12-09 Cdk4及6抑制劑及氟維司群用於治療先前以cdk4及6抑制劑治療的患者之荷爾蒙受體陽性、人類表皮生長因子受體2陰性之晚期或轉移性乳癌 TW202342044A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163288179P 2021-12-10 2021-12-10
US63/288,179 2021-12-10
US202263321218P 2022-03-18 2022-03-18
US63/321,218 2022-03-18

Publications (1)

Publication Number Publication Date
TW202342044A true TW202342044A (zh) 2023-11-01

Family

ID=85157124

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111147357A TW202342044A (zh) 2021-12-10 2022-12-09 Cdk4及6抑制劑及氟維司群用於治療先前以cdk4及6抑制劑治療的患者之荷爾蒙受體陽性、人類表皮生長因子受體2陰性之晚期或轉移性乳癌

Country Status (10)

Country Link
US (1) US20240398832A1 (https=)
EP (1) EP4444315A1 (https=)
JP (1) JP2023086719A (https=)
KR (1) KR20240118134A (https=)
AU (1) AU2022408062B2 (https=)
CA (1) CA3240454A1 (https=)
IL (1) IL313422A (https=)
MX (1) MX2024007015A (https=)
TW (1) TW202342044A (https=)
WO (1) WO2023107525A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
KR20180119570A (ko) * 2016-03-15 2018-11-02 메리맥 파마슈티컬즈, 인크. 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
CN115624552A (zh) 2017-05-02 2023-01-20 伊莱利利公司 用于乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合
WO2021030248A1 (en) * 2019-08-12 2021-02-18 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant

Also Published As

Publication number Publication date
US20240398832A1 (en) 2024-12-05
AU2022408062B2 (en) 2025-08-14
CA3240454A1 (en) 2023-06-15
WO2023107525A1 (en) 2023-06-15
IL313422A (en) 2024-08-01
MX2024007015A (es) 2024-06-19
EP4444315A1 (en) 2024-10-16
AU2022408062A1 (en) 2024-06-20
KR20240118134A (ko) 2024-08-02
JP2023086719A (ja) 2023-06-22

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
EP3923941A1 (en) Pharmaceutical combination comprising tno155 and ribociclib
US20260041695A1 (en) Combination therapies for treatment of breast cancer
JP2019511526A (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
TW202120096A (zh) 使用包含atp競爭性akt抑制劑、cdk4/6抑制劑及氟維司群之組合療法治療乳癌
US20250319084A1 (en) Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
JP2020023497A (ja) 組合せ医薬
JP2024509823A (ja) アムセネストラントおよびパルボシクリブによる乳がんの処置
EP4663633A1 (en) Combined pharmaceutical composition of substituted 2-hydrogen-pyrazole derivative and use thereof
TW202342044A (zh) Cdk4及6抑制劑及氟維司群用於治療先前以cdk4及6抑制劑治療的患者之荷爾蒙受體陽性、人類表皮生長因子受體2陰性之晚期或轉移性乳癌
TW202400136A (zh) 以安森司群(amcenestrant)治療乳癌
EA051022B1 (ru) Ингибитор cdk4 и 6 в комбинации с фулвестрантом для лечения положительного по гормональному рецептору, отрицательного по рецептору 2 эпидермального фактора человека распространенного или метастатического рака молочной железы у пациентов, ранее получавших лечение ингибитором cdk4 и 6
CN118660706A (zh) Cdk4和6抑制剂与氟维司群组合用于在cdk4和6抑制剂先前治疗的患者中治疗激素受体阳性、人表皮生长因子受体2阴性晚期或转移性乳腺癌
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
CN118804747A (zh) 用安森司群治疗乳腺癌
WO2022123419A1 (en) Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
WO2023204800A1 (en) Combination therapy
JP2019131559A (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ